Clinical Trial Update: Study to Evaluate the Efficacy and Safety of Subsequent Treatment With the Zevalin (Ibritumomab Tiuxetan) Study in Patients With Follicular Grade I-II Lymphoma After 4 Cycles of Fludarabine-Mitoxantrone-Rituximab (FMR) Therapy [Phase 2]

View source ↗

Summary

A Phase 2 trial assessing the efficacy and safety of Zevalin (ibritumomab tiuxetan) as a subsequent treatment in patients with follicular lymphoma after complet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• Zevalin (ibritumomab tiuxetan)

Snippet

Sponsor: University of Bologna | Conditions: Follicular Lymphoma | Phase 2 | Status: COMPLETED